Fig. 5

In vivo antitumor analysis of PD-1@RSL3 NPs. a Schedule of PD-1@RSL3 NPs treatment in 4T1 tumor-bearing mice. PBS, RSL3 (5 mg/kg), Blank@RSL3 NPs (NVs: 25 mg/kg, protein mass; RSL3: 5 mg/kg), PD-1 NVs (NVs: 25 mg/kg, protein mass), aPD-L1 + RSL3 NPs (aPD-L1: 2.0 mg/kg; RSL3: 5 mg/kg), or PD-1@RSL3 NPs (NVs: 25 mg/kg, protein mass RSL3: 5 mg/kg). b Tumor growth curves of 4T1-tumor-bearing mice receiving different treatments (n ≥ 5). c Survival rates of mice receiving different treatments. d Excised tumor weight in different groups. e Body weight of mice receiving different treatments. G1, PBS; G2, RSL3; G3, Blank@RSL3; G4, PD-1 NVs; G5, aPD-L1 + RSL3 NPs; G6, PD-1@RSL3. Data were shown as mean ± SD. P values are from one-way ANOVA followed by Tukey’s post-test (B, D) or log-rank (Mantel–Cox) test (C). *P < 0.05, **P < 0.01, ***P < 0.001